CN112055754A - 调节Ras泛素化的方法 - Google Patents
调节Ras泛素化的方法 Download PDFInfo
- Publication number
- CN112055754A CN112055754A CN201980026875.XA CN201980026875A CN112055754A CN 112055754 A CN112055754 A CN 112055754A CN 201980026875 A CN201980026875 A CN 201980026875A CN 112055754 A CN112055754 A CN 112055754A
- Authority
- CN
- China
- Prior art keywords
- ras
- compound
- nedd4
- protein
- optionally
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims description 87
- 230000034512 ubiquitination Effects 0.000 title claims description 45
- 238000010798 ubiquitination Methods 0.000 title claims description 43
- 102000016914 ras Proteins Human genes 0.000 claims abstract description 138
- 108010014186 ras Proteins Proteins 0.000 claims abstract description 138
- 150000001875 compounds Chemical class 0.000 claims abstract description 125
- 239000003814 drug Substances 0.000 claims abstract description 35
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 29
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 8
- 210000004027 cell Anatomy 0.000 claims description 138
- 108090000623 proteins and genes Proteins 0.000 claims description 99
- 102000004169 proteins and genes Human genes 0.000 claims description 93
- 101710113436 GTPase KRas Proteins 0.000 claims description 53
- 230000015556 catabolic process Effects 0.000 claims description 37
- 238000006731 degradation reaction Methods 0.000 claims description 37
- 238000000338 in vitro Methods 0.000 claims description 29
- 102100039788 GTPase NRas Human genes 0.000 claims description 24
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 claims description 24
- 102200006531 rs121913529 Human genes 0.000 claims description 24
- 230000014509 gene expression Effects 0.000 claims description 18
- 230000001419 dependent effect Effects 0.000 claims description 13
- 102200006532 rs112445441 Human genes 0.000 claims description 13
- 102200006525 rs121913240 Human genes 0.000 claims description 13
- 150000007523 nucleic acids Chemical class 0.000 claims description 12
- 230000001105 regulatory effect Effects 0.000 claims description 12
- 108020004707 nucleic acids Proteins 0.000 claims description 11
- 102000039446 nucleic acids Human genes 0.000 claims description 11
- 102220014333 rs112445441 Human genes 0.000 claims description 10
- -1 small molecule compounds Chemical class 0.000 claims description 10
- 230000000694 effects Effects 0.000 claims description 9
- 230000002018 overexpression Effects 0.000 claims description 8
- 230000002829 reductive effect Effects 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 239000003153 chemical reaction reagent Substances 0.000 claims description 7
- 230000001332 colony forming effect Effects 0.000 claims description 7
- 229940002612 prodrug Drugs 0.000 claims description 7
- 239000000651 prodrug Substances 0.000 claims description 7
- 102200006539 rs121913529 Human genes 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 6
- 230000001737 promoting effect Effects 0.000 claims description 6
- 230000007423 decrease Effects 0.000 claims description 5
- 230000002068 genetic effect Effects 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 108020004999 messenger RNA Proteins 0.000 claims description 5
- 210000004881 tumor cell Anatomy 0.000 claims description 5
- 230000003247 decreasing effect Effects 0.000 claims description 4
- 238000012360 testing method Methods 0.000 claims description 4
- 102000008300 Mutant Proteins Human genes 0.000 claims description 3
- 108010021466 Mutant Proteins Proteins 0.000 claims description 3
- 230000002222 downregulating effect Effects 0.000 claims description 3
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 claims description 2
- 229940000406 drug candidate Drugs 0.000 claims description 2
- 239000013613 expression plasmid Substances 0.000 claims description 2
- 230000009368 gene silencing by RNA Effects 0.000 claims description 2
- 238000010362 genome editing Methods 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 239000012453 solvate Substances 0.000 claims description 2
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 abstract description 5
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 24
- 238000002474 experimental method Methods 0.000 description 24
- 239000000203 mixture Substances 0.000 description 21
- 229940079593 drug Drugs 0.000 description 20
- 201000010099 disease Diseases 0.000 description 18
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 17
- 229920001817 Agar Polymers 0.000 description 16
- 239000008272 agar Substances 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- 239000012528 membrane Substances 0.000 description 15
- 238000001262 western blot Methods 0.000 description 14
- 102000007469 Actins Human genes 0.000 description 13
- 108010085238 Actins Proteins 0.000 description 13
- 201000011510 cancer Diseases 0.000 description 13
- 239000002609 medium Substances 0.000 description 12
- 239000013612 plasmid Substances 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 11
- 238000001890 transfection Methods 0.000 description 11
- 239000006180 TBST buffer Substances 0.000 description 10
- 239000011550 stock solution Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical group CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 238000001514 detection method Methods 0.000 description 9
- 239000013598 vector Substances 0.000 description 9
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 230000003993 interaction Effects 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 238000012216 screening Methods 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 229910002092 carbon dioxide Inorganic materials 0.000 description 7
- 230000001404 mediated effect Effects 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- 230000017854 proteolysis Effects 0.000 description 7
- 241000283707 Capra Species 0.000 description 6
- 206010009944 Colon cancer Diseases 0.000 description 6
- 102000005720 Glutathione transferase Human genes 0.000 description 6
- 108010070675 Glutathione transferase Proteins 0.000 description 6
- 150000001413 amino acids Chemical group 0.000 description 6
- 239000011324 bead Substances 0.000 description 6
- 239000013592 cell lysate Substances 0.000 description 6
- 208000029742 colonic neoplasm Diseases 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 230000003834 intracellular effect Effects 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 102000013415 peroxidase activity proteins Human genes 0.000 description 6
- 108040007629 peroxidase activity proteins Proteins 0.000 description 6
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 229920000936 Agarose Polymers 0.000 description 5
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 5
- 238000012258 culturing Methods 0.000 description 5
- 238000007747 plating Methods 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 108091027967 Small hairpin RNA Proteins 0.000 description 4
- 230000003698 anagen phase Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 238000007865 diluting Methods 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 238000013537 high throughput screening Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000007789 sealing Methods 0.000 description 4
- 239000004055 small Interfering RNA Substances 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 3
- 101150040459 RAS gene Proteins 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 102000044159 Ubiquitin Human genes 0.000 description 3
- 108090000848 Ubiquitin Proteins 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 230000005757 colony formation Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000000111 isothermal titration calorimetry Methods 0.000 description 3
- 210000003292 kidney cell Anatomy 0.000 description 3
- 230000002132 lysosomal effect Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 108700042226 ras Genes Proteins 0.000 description 3
- 239000011535 reaction buffer Substances 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 3
- 239000012096 transfection reagent Substances 0.000 description 3
- 239000012130 whole-cell lysate Substances 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102000002110 C2 domains Human genes 0.000 description 2
- 108050009459 C2 domains Proteins 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 102100035493 E3 ubiquitin-protein ligase NEDD4-like Human genes 0.000 description 2
- 101710155393 E3 ubiquitin-protein ligase NEDD4-like Proteins 0.000 description 2
- 102000018898 GTPase-Activating Proteins Human genes 0.000 description 2
- 108091006094 GTPase-accelerating proteins Proteins 0.000 description 2
- 206010064571 Gene mutation Diseases 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 229940079156 Proteasome inhibitor Drugs 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 150000008052 alkyl sulfonates Chemical class 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 2
- 210000004507 artificial chromosome Anatomy 0.000 description 2
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 238000011072 cell harvest Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 238000003197 gene knockdown Methods 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 238000002493 microarray Methods 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000003207 proteasome inhibitor Substances 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000007711 solidification Methods 0.000 description 2
- 230000008023 solidification Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- JWDLEVZYUTZUBA-UHFFFAOYSA-N 2-amino-3,7-dihydropurin-6-one;phosphono dihydrogen phosphate Chemical compound OP(O)(=O)OP(O)(O)=O.O=C1NC(N)=NC2=C1NC=N2 JWDLEVZYUTZUBA-UHFFFAOYSA-N 0.000 description 1
- WOGWYSWDBYCVDY-UHFFFAOYSA-N 2-chlorocyclohexa-2,5-diene-1,4-dione Chemical compound ClC1=CC(=O)C=CC1=O WOGWYSWDBYCVDY-UHFFFAOYSA-N 0.000 description 1
- KPGXRSRHYNQIFN-UHFFFAOYSA-L 2-oxoglutarate(2-) Chemical compound [O-]C(=O)CCC(=O)C([O-])=O KPGXRSRHYNQIFN-UHFFFAOYSA-L 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 108700033932 EC 6.2.1.45 Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 241001524679 Escherichia virus M13 Species 0.000 description 1
- XZWYTXMRWQJBGX-VXBMVYAYSA-N FLAG peptide Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)CC1=CC=C(O)C=C1 XZWYTXMRWQJBGX-VXBMVYAYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010042602 Supraventricular extrasystoles Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 101710132695 Ubiquitin-conjugating enzyme E2 Proteins 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 150000008055 alkyl aryl sulfonates Chemical class 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000009833 antibody interaction Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 125000005228 aryl sulfonate group Chemical group 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical group [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 230000007364 biochemical regulatory process Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 238000000749 co-immunoprecipitation Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical group C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 1
- 235000013928 guanylic acid Nutrition 0.000 description 1
- 235000015220 hamburgers Nutrition 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical class I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L magnesium chloride Substances [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000008172 membrane trafficking Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000004001 molecular interaction Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 238000010379 pull-down assay Methods 0.000 description 1
- 108010077182 raf Kinases Proteins 0.000 description 1
- 102000009929 raf Kinases Human genes 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000014493 regulation of gene expression Effects 0.000 description 1
- 230000026267 regulation of growth Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/25—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving enzymes not classifiable in groups C12Q1/26 - C12Q1/66
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/9015—Ligases (6)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
提供了E3泛素连接酶Nedd4‑1在制备抑制Ras蛋白水平的药物中的用途。还提供了在制备预防和/或治疗肿瘤的药物或者延长有机体寿命的药物中的用途。
Description
PCT国内申请，说明书已公开。
Claims (10)
- PCT国内申请，权利要求书已公开。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810391658.8A CN108546731A (zh) | 2018-04-27 | 2018-04-27 | 调节Ras泛素化的方法 |
| CN2018103916588 | 2018-04-27 | ||
| PCT/CN2019/084176 WO2019206203A1 (zh) | 2018-04-27 | 2019-04-25 | 调节Ras泛素化的方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112055754A true CN112055754A (zh) | 2020-12-08 |
Family
ID=63512828
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810391658.8A Pending CN108546731A (zh) | 2018-04-27 | 2018-04-27 | 调节Ras泛素化的方法 |
| CN201980026875.XA Pending CN112055754A (zh) | 2018-04-27 | 2019-04-25 | 调节Ras泛素化的方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810391658.8A Pending CN108546731A (zh) | 2018-04-27 | 2018-04-27 | 调节Ras泛素化的方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20210228552A1 (zh) |
| EP (1) | EP3786304A4 (zh) |
| JP (1) | JP2021518751A (zh) |
| CN (2) | CN108546731A (zh) |
| AU (1) | AU2019258792A1 (zh) |
| WO (1) | WO2019206203A1 (zh) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108948002A (zh) * | 2017-05-19 | 2018-12-07 | 厦门大学 | 五元并六元氮杂芳环类化合物、其制备方法、药用组合物及其应用 |
| CN108546731A (zh) * | 2018-04-27 | 2018-09-18 | 厦门大学 | 调节Ras泛素化的方法 |
| CN114196650B (zh) * | 2021-12-19 | 2023-07-25 | 中国人民解放军军事科学院军事医学研究院 | E3泛素连接酶hrd1在调控初级纤毛发生中的应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170291958A1 (en) * | 2016-04-11 | 2017-10-12 | New York University | Compositions and Methods For the Modulation of Ras Proteins |
| CN107951879A (zh) * | 2016-10-14 | 2018-04-24 | 武汉臻智生物科技有限公司 | 聚醚类化合物在制备药物中的用途及筛选抗癌药物的方法 |
| CN110869369B (zh) * | 2017-05-19 | 2022-06-28 | 厦门大学 | 五元并六元氮杂芳环类化合物、其制备方法、药用组合物及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7229619B1 (en) | 2000-11-28 | 2007-06-12 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
| US7186716B2 (en) * | 2002-08-12 | 2007-03-06 | Sugen, Inc. | 3-Pyrrol-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors |
| US9597346B2 (en) * | 2010-01-15 | 2017-03-21 | Cornell University | Methods for reducing protein levels in a cell |
| KR101533469B1 (ko) * | 2010-02-03 | 2015-07-02 | 연세대학교 산학협력단 | Ｒａｓ의 Ｔｈｒ-144번과 Ｔｈｒ-148번의 인산화의 감지를 통한 암 진단 방법, 항암제 스크리닝 및 약효테스트 방법 |
| WO2012113061A1 (en) * | 2011-02-23 | 2012-08-30 | Miami Mice Research Corp | Cancer diagnosis and treatment |
| CN104673762B (zh) * | 2015-01-19 | 2017-10-20 | 江苏大学 | 抗泛素连接酶Nedd4‑1的特异性抗体及其应用 |
| CN108546731A (zh) * | 2018-04-27 | 2018-09-18 | 厦门大学 | 调节Ras泛素化的方法 |
-
2018
- 2018-04-27 CN CN201810391658.8A patent/CN108546731A/zh active Pending
-
2019
- 2019-04-25 EP EP19792125.7A patent/EP3786304A4/en not_active Withdrawn
- 2019-04-25 WO PCT/CN2019/084176 patent/WO2019206203A1/zh active Application Filing
- 2019-04-25 CN CN201980026875.XA patent/CN112055754A/zh active Pending
- 2019-04-25 US US17/050,818 patent/US20210228552A1/en active Pending
- 2019-04-25 AU AU2019258792A patent/AU2019258792A1/en not_active Abandoned
- 2019-04-25 JP JP2020545588A patent/JP2021518751A/ja active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170291958A1 (en) * | 2016-04-11 | 2017-10-12 | New York University | Compositions and Methods For the Modulation of Ras Proteins |
| CN107951879A (zh) * | 2016-10-14 | 2018-04-24 | 武汉臻智生物科技有限公司 | 聚醚类化合物在制备药物中的用途及筛选抗癌药物的方法 |
| CN110869369B (zh) * | 2017-05-19 | 2022-06-28 | 厦门大学 | 五元并六元氮杂芳环类化合物、其制备方法、药用组合物及其应用 |
Non-Patent Citations (1)
| Title |
|---|
| ZENG TAOLING等: ""Impeded Nedd4-1-Mediated Ras Degradation Underlies Ras-Driven Tumorigenesis"", 《CELL REPORTS》, vol. 7, no. 3, pages 1 - 2 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021518751A (ja) | 2021-08-05 |
| WO2019206203A1 (zh) | 2019-10-31 |
| EP3786304A1 (en) | 2021-03-03 |
| EP3786304A4 (en) | 2022-01-05 |
| CN108546731A (zh) | 2018-09-18 |
| US20210228552A1 (en) | 2021-07-29 |
| AU2019258792A1 (en) | 2020-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Itoh et al. | Golgi-resident small GTPase Rab33B interacts with Atg16L and modulates autophagosome formation | |
| Andrews et al. | Cytoplasmic localized ubiquitin ligase cullin 7 binds to p53 and promotes cell growth by antagonizing p53 function | |
| Quilliam et al. | M-Ras/R-Ras3, a transforming ras protein regulated by Sos1, GRF1, and p120 Ras GTPase-activating protein, interacts with the putative Ras effector AF6 | |
| Malaney et al. | PTEN physically interacts with and regulates E2F1-mediated transcription in lung cancer | |
| WO1998045708A1 (en) | Study and treatment of diseases related to specific cellular functions of receptor protein tyrosine kinases | |
| Chen et al. | Mammalian tumor suppressor Int6 specifically targets hypoxia inducible factor 2α for degradation by hypoxia-and pVHL-independent regulation | |
| CN112055754A (zh) | 调节Ras泛素化的方法 | |
| KR20060121842A (ko) | β-카테닌/ＴＣＦ에 의해 활성화되는 전사의 조절 | |
| Shalhout et al. | YAP-dependent proliferation by a small molecule targeting annexin A2 | |
| JP2008505307A (ja) | ＨＡＵＳＰ−Ｍｄｍ２相互作用及びその使用 | |
| Mishra et al. | E6-AP association promotes SOD1 aggresomes degradation and suppresses toxicity | |
| Braganza et al. | UBE3B is a calmodulin-regulated, mitochondrion-associated E3 ubiquitin ligase | |
| Gong et al. | Different SUMO paralogues determine the fate of wild-type and mutant CFTRs: biogenesis versus degradation | |
| KR101321284B1 (ko) | 프로게린 발현 억제제를 유효성분으로 함유하는 노화 관련 질환 치료용 약학조성물 및 상기 프로게린 발현 억제제의 스크리닝 방법 | |
| US20090136482A1 (en) | Drug target protein and target gene, and screening method | |
| Luo et al. | A RasGAP, DAB2IP, regulates lipid droplet homeostasis by serving as GAP toward RAB40C | |
| US8058009B2 (en) | Target protein and target gene in drug designing and screening method | |
| CN110237257B (zh) | Ube3a泛素化PP2A激活因子PTPA在治疗天使综合症和孤独症中的应用 | |
| Klinke et al. | A Drosophila melanogaster model for TMEM43-related arrhythmogenic right ventricular cardiomyopathy type 5 | |
| Hussein et al. | A novel regulatory role of TRAPPC9 in L‐plastin‐mediated osteoclast actin ring formation | |
| US20230139516A1 (en) | Ripk2 inhibition for the treatment of cancer | |
| MacPartlin et al. | Phosphorylation and stabilization of TAp63γ by IκB kinase-β | |
| JP2002517998A (ja) | ｐ２７（ＫＩＰ１）のＦＫＢＰ−１２との相互作用 | |
| Yang et al. | TRIM25-mediated ubiquitination of G3BP1 regulates the proliferation and migration of human neuroblastoma cells | |
| US9874553B2 (en) | Targeted chemical high-throughput screening method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40038482 Country of ref document: HK |